While carefully timed light exposure may address sleep problems associated with circadian rhythm disturbances, studies that examine light therapies in the context of sleep disorders have been largely lacking in measures of adherence and acceptability of these approaches.
Idorsia announced positive topline results from a phase 3 study of daridorexant, an investigational dual orexin receptor antagonist, for the treatment of insomnia.
Positive topline data from the phase 3 REST-ON trial evaluating FT218 (Avadel), an investigational, once-nightly formulation of sodium oxybate, showed that the treatment led to clinically meaningful improvement in patients with narcolepsy.
Researchers suggest the Narcolepsy Severity Scale be used more frequently in the clinical settings and future narcolepsy studies.
Children with congenital heart disease and comorbid obstructive sleep apnea are at increased risk for impaired neurocognition compared with children with congenital heart disease who do not have comorbid OSA.
As people around the world face prolonged periods of confinement to their homes during the COVID-19 pandemic, stress levels may disrupt sleep patterns and worsen overall mental health.
The FDA has approved Somryst™ (Pear Therapeutics), a prescription digital therapeutic (PDT) intended for the treatment of patients 22 years of age and older with chronic insomnia.
The FDA has accepted for Priority Review the New Drug Application for JZP-258 for the treatment of cataplexy or excessive daytime sleepiness in patients aged ≥7 years with narcolepsy.
Depression contributed to elevated ratings in patients with MDD on items related to perceived inability to cope with the negative consequences of disturbed sleep and reported tendency to cancel social plans after poor sleep.
Overall, in all patients with MDD, sleep ultradian cycle number was positively associated with REMS percentage, REMS duration, and REMS/NREMS ratio and negatively associated with REM latency.
